Ovid Therapeutics (OVID) Analyst & Key Data

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

11

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.69

Median Target+79.55%

$4.83

Potential upside vs current price

DCF Value-125.28%

-$0.68

Potential downside vs current price

Current Stock Price

$2.69

Median Target+79.55%

$4.83

Potential upside vs current price

DCF Value-125.28%

-$0.68

Potential downside vs current price

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

11

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.69

Median Target+79.55%

$4.83

Potential upside vs current price

DCF Value-125.28%

-$0.68

Potential downside vs current price

Current Stock Price

$2.69

Median Target+79.55%

$4.83

Potential upside vs current price

DCF Value-125.28%

-$0.68

Potential downside vs current price

Ovid Therapeutics Inc.